Aumolertinib

Aumolertinib
Clinical data
Trade names	Ameile
Other names	Almonertinib; HS-10296
ATC code	L01EB11 ( WHO );
Legal status
Legal status	CN: Rx-only;
Identifiers
	IUPAC name N-[5-[[4-(1-Cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide;
CAS Number	1899921-05-1 ;
PubChem CID	121280087 ;
IUPHAR/BPS	11136 ;
DrugBank	DB16640 ;
ChemSpider	75535991 ;
UNII	T4RS462G19 ;
ChEMBL	ChEMBL4761468 ;
Chemical and physical data
Formula	C30H35N7O2
Molar mass	525.657 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)C5CC5)OC;
	InChI InChI=1S/C30H35N7O2/c1-6-29(38)32-24-17-25(28(39-5)18-27(24)36(4)16-15-35(2)3)34-30-31-14-13-23(33-30)22-19-37(20-11-12-20)26-10-8-7-9-21(22)26/h6-10,13-14,17-20H,1,11-12,15-16H2,2-5H3,(H,32,38)(H,31,33,34); Key:DOEOECWDNSEFDN-UHFFFAOYSA-N;

Last updated September 28, 2025

Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.^[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).^[2]

In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.^[3]^[4]

References

↑ Shirley M, Keam SJ (April 2022). "Aumolertinib: A Review in Non-Small Cell Lung Cancer". Drugs. 82 (5): 577–584. doi:10.1007/s40265-022-01695-2. PMID 35305259.
↑ Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, et al. (2023). "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology. 41 (16) TPS9153. doi:10.1200/JCO.2023.41.16_suppl.TPS9153.
↑ "Almonertinib Approved in China for EGFR T79M+ NSCLC". onclive.com. 19 March 2020.
↑ Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. (March 2022). "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial". Journal of Thoracic Oncology. 17 (3): 411–422. doi: 10.1016/j.jtho.2021.10.024 . PMID 34801749.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Shirley M, Keam SJ (April 2022). "Aumolertinib: A Review in Non-Small Cell Lung Cancer". Drugs. 82 (5): 577–584. doi:10.1007/s40265-022-01695-2. PMID 35305259.

[2] Johnson ML, Miller VA, Patel S, Zhao Y, Cheng L, Ali SM, et al. (2023). "Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE)". Journal of Clinical Oncology. 41 (16) TPS9153. doi:10.1200/JCO.2023.41.16_suppl.TPS9153.

[3] "Almonertinib Approved in China for EGFR T79M+ NSCLC". onclive.com. 19 March 2020.

[4] Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, et al. (March 2022). "Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial". Journal of Thoracic Oncology. 17 (3): 411–422. doi: 10.1016/j.jtho.2021.10.024 . PMID 34801749.

[1]

[2]

[3]

[4]